What is the difference between implantable and wearable CGM technology?

Implantable CGM systems, like Senseonics' Eversense, place a sensor under the skin that can last for months, while wearable systems, like DexCom's G-series, use adhesive sensors applied to the skin's surface that are typically replaced more frequently, with each approach offering different tradeoffs in convenience, wear duration, and insertion procedure.

What metrics matter most when comparing SENS and DXCM?

For Senseonics, watch commercial partnership execution and sensor longevity improvements. For DexCom, focus on new sensor generation adoption rates and expansion into broader diabetes and wellness market segments.

How does market scale differ between Senseonics and DexCom?

DexCom operates at vastly greater commercial scale with an established global sales infrastructure and broad physician adoption, while Senseonics remains a much smaller company that relies on a commercialization partnership to reach patients, making the two companies very different in terms of financial stability and market reach.

How is the AI score calculated?

The AI score is a composite signal incorporating fundamental quality, valuation, momentum, analyst sentiment, and risk factors. A higher score indicates a more favorable overall setup relative to the market at the time of the latest update.

Data as of: August 23, 2026

brimindinvest.com / compare / sens-vs-dxcmLIVE

SENS

Senseonics Holdings, Inc. · MedTech

N/A

N/A this month

VERSUS

COMPARE

DXCM

DexCom, Inc. · MedTech

N/A

N/A this month

Comparison scoreboard

MIXED SETUP

AI Scorei

SENS N/A

DXCM N/A

1Y Returni

SENS N/A

DXCM N/A

Fwd P/Ei

SENS N/A

DXCM N/A

Target Up.i

SENS N/A

DXCM N/A

Op. Margini

SENS N/A

DXCM N/A

Quick take

SENS vs DXCM Stock Comparison: AI Score, Valuation, Performance and Upside

ShareX LinkedIn Reddit Facebook WhatsApp

Senseonics and DexCom both compete in continuous glucose monitoring, but DexCom is the established wearable sensor market leader with far greater scale, while Senseonics offers a niche implantable alternative dependent on a commercial partnership for distribution reach.

SENS offers a speculative bet on a differentiated implantable CGM technology reaching wider adoption, while DXCM offers exposure to the established, scaled wearable CGM leader. The choice comes down to risk tolerance for a smaller niche player versus a proven market leader.

Want a full valuation workup? 46-section report — AI Score, Monte Carlo forecast, bull/bear case, DCF, and more.

DXCM Report

Normalized 1Y performance

SENS

DXCM

Not enough data to chart yet.

Recent returns

SENS

DXCM

Not enough data to chart yet.

Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

SENS

Price target data unavailable

N/A

DXCM

Price target data unavailable

N/A

Who should consider this stock?

SENS may suit investors who:

Want speculative exposure to a differentiated implantable CGM technology
Believe extended-wear implantable sensors can carve out a lasting niche among certain patients
Are comfortable with the higher risk profile of a smaller, partnership-dependent medtech company
See global diabetes prevalence trends as a long-term tailwind for CGM adoption broadly

DXCM may suit investors who:

Prefer the established leader in wearable continuous glucose monitoring technology
Value a broader addressable market spanning intensive insulin users and beyond
Want exposure to CGM growth without the concentration risk of a single niche product
Believe continued sensor innovation will sustain DexCom's competitive position

Performance & AI score

Performance & AI score
Metric	SENS	DXCM
AI scorei	N/A	N/A
AI ranki	N/A	N/A
Latest closei	N/A	N/A

Valuation & upside potential

Valuation & upside potential
Metric	SENS	DXCM
Market capi	N/A	N/A
Trailing P/Ei	N/A	N/A
Forward P/Ei	N/A	N/A
Price/Salesi	N/A	N/A
EV/Revenuei	N/A	N/A
Analyst targeti	N/A	N/A
Target upsidei	N/A	N/A

Full DCF model for DXCM

Growth, profitability & risk

Growth, profitability & risk
Metric	SENS	DXCM
Revenue growthi	N/A	N/A
Earnings growthi	N/A	N/A
EPS growthi	N/A	N/A
FCF margini	N/A	N/A
Operating margini	N/A	N/A
Profit margini	N/A	N/A
ROIC proxyi	N/A	N/A
Return on equityi	N/A	N/A
Dividend yieldi	N/A	N/A
Payout ratioi	N/A	N/A
Dividend growth streaki	N/A	N/A
Betai	N/A	N/A
Debt/equityi	N/A	N/A
Current ratioi	N/A	N/A
Quick ratioi	N/A	N/A

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

SENS max drawdowniN/A

DXCM max drawdowniN/A

SENS max wkly dropiN/A

DXCM max wkly dropiN/A

5Y risk snapshot

SENS max drawdowniN/A

DXCM max drawdowniN/A

SENS max wkly dropiN/A

DXCM max wkly dropiN/A

10Y risk snapshot

SENS max drawdowniN/A

DXCM max drawdowniN/A

SENS max wkly dropiN/A

DXCM max wkly dropiN/A

Performance metrics by period

Performance metrics by period
Period	Metric	SENS	DXCM
1Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
5Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
10Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A

AI Prediction Signali

Members only

Next 5 trading days

SENS

+2.8%BUY

DXCM

+1.1%HOLD

Next 30 trading days

SENS

+6.4%BUY

DXCM

+3.2%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Business comparison

Business comparison
Category	SENS	DXCM
Company	Senseonics Holdings, Inc.	DexCom, Inc.
Sector	MedTech	MedTech
Industry	N/A	N/A
Core business	A medical technology company that develops implantable continuous glucose monitoring systems, offering an under-the-skin sensor approach as an alternative to adhesive wearable sensors for diabetes management.	A medical device company that designs and markets wearable continuous glucose monitoring systems used by people with diabetes to track glucose levels in real time without routine fingerstick testing.
Investor focus	Commercial partnership execution, sensor longevity improvements, and adoption rates among patients seeking an alternative to daily-wear sensor patches.	New sensor generation adoption, expansion into non-intensive insulin users and broader consumer health markets, and international growth.

SENS strengths

Implantable sensor design offers a differentiated form factor that appeals to patients who dislike adhesive wearable sensors
Extended sensor wear duration compared to some wearable alternatives can reduce the frequency of sensor changes for users
Strategic commercialization partnership provides access to broader sales and distribution infrastructure than the company could build alone

DXCM strengths

Established market leadership in wearable CGM technology provides brand recognition and physician trust built over many product generations
Simple self-applied wearable design lowers the adoption barrier relative to implantable alternatives
Expanding addressable market beyond intensive insulin users into broader diabetes and wellness segments supports a longer growth runway

Risks to watch — SENS

Small revenue base relative to larger CGM competitors leaves the company more exposed to shifts in partner strategy or funding needs
Implantation procedure requirement creates a higher barrier to adoption compared to simple self-applied wearable sensors
Competitive pressure from larger, well-capitalized CGM makers continues to intensify across the diabetes technology market

Risks to watch — DXCM

Intensifying competition from other wearable CGM makers pressures pricing and market share over time
Reliance on continued innovation to maintain differentiation as sensor technology matures across the industry
Reimbursement policy changes from insurers and government payers can affect the pace of new patient adoption

Frequently asked questions

SENS offers speculative exposure to a differentiated implantable CGM technology, while DXCM offers exposure to the established, scaled wearable CGM market leader. The better choice depends on your risk tolerance and whether you prefer a niche technology bet or a proven market leader.

Interactive comparison engine

Compare more than two at a time

This page is a fixed writeup on SENS and DXCM. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.

Up to 5 tickers at once

Add three more names beside SENS and DXCM, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.

Scoreboard verdict

AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.

Full risk suite

Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.

Correlation heatmap

Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.

Valuation vs profitability

A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.

Holdings overlap and CSV export

For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.

Open SENS vs DXCM in the engine See what's included

Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

In-Depth Reports

Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.

DXCM Report

Related comparisons